Ameriprise
ADCT icon

Ameriprise’s ADC Therapeutics ADCT Stock Holding History

Ameriprise’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-89,526
Closed -$192K – 3886
2023
Q2 		$192K Sell
89,526
-23,380
-21% -$52.6K ﹤0.01% 3736
2023
Q1 		$220K Buy
112,906
+34,236
+44% +$126K ﹤0.01% 3705
2022
Q4 		$302K Buy
78,670
+1,567
+2% +$6.27K ﹤0.01% 3582
2022
Q3 		$372K Sell
77,103
-2,873
-4% -$20.8K ﹤0.01% 3501
2022
Q2 		$636K Buy
79,976
+4,946
+7% +$46.8K ﹤0.01% 3312
2022
Q1 		$1.1M Buy
75,030
+8,678
+13% +$138K ﹤0.01% 3172
2021
Q4 		$1.34M Sell
66,352
-2,463
-4% -$59.4K ﹤0.01% 3121
2021
Q3 		$1.87M Buy
68,815
+1,781
+3% +$45.6K ﹤0.01% 2898
2021
Q2 		$1.64M Buy
67,034
+5,615
+9% +$130K ﹤0.01% 3005
2021
Q1 		$1.5M Sell
61,419
-12,683
-17% -$367K ﹤0.01% 2963
2020
Q4 		$2.37M Buy
74,102
+18,177
+33% +$596K ﹤0.01% 2703
2020
Q3 		$1.84M Sell
55,925
-8,785
-14% -$380K ﹤0.01% 2711
2020
Q2 		$3.03M Buy
+64,710
New +$2.46M ﹤0.01% 2393

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $100M AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ameriprise's ADCT Position: Q3 2023 in Review

Ameriprise sold out of ADC Therapeutics (ADCT) in Q3 2023, closing a stake of 89,526 shares — an estimated $192K sold.

Ameriprise first reported a position in ADCT in Q2 2020 and held it in 13 quarters. The position peaked at $3.03M in Q2 2020. 41 funds tracked by Wall St. Rank hold ADCT as of Q3 2023.

  • Ameriprise reported no remaining ADC Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Ameriprise sold 89,526 ADC Therapeutics shares in Q3 2023, an estimated $192K.
  • Ameriprise first reported a position in ADC Therapeutics in Q2 2020 and held it in 13 quarters.
  • Ameriprise's ADC Therapeutics position peaked at $3.03M in Q2 2020.
  • 41 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2023.

Based on Ameriprise's 13F filing for Q3 2023, filed 14 Nov 2023.